Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
News for Incyte Genomics Inc (Nasdaq: INCY), operating as Incyte Corporation, centers on its activities as a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. Company releases describe a portfolio of first‑in‑class medicines and a pipeline of proprietary therapeutics, making INCY news particularly relevant for investors and healthcare observers following cancer and immune‑related drug development.
Recent headlines highlight late-stage clinical trial results and regulatory milestones. Incyte has reported positive topline data from the Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R‑CHOP as first‑line therapy for diffuse large B‑cell lymphoma, meeting primary and key secondary endpoints. Other news covers European Commission and Japanese approvals of Minjuvi in combination regimens for relapsed or refractory follicular lymphoma and DLBCL, underscoring the company’s role in B‑cell lymphoma treatment.
In immuno‑oncology, Incyte Biosciences Japan G.K. has announced approval of Zynyz (retifanlimab) with platinum‑based chemotherapy as first‑line treatment for advanced squamous cell carcinoma of the anal canal, following earlier U.S. approval in a similar setting. Additional coverage describes submissions to European regulators and the broader POD1UM clinical program evaluating retifanlimab across solid tumors.
News flow also features pipeline updates for INCA033989, a first‑in‑class mutCALR‑targeted monoclonal antibody for myeloproliferative neoplasms. Incyte has disclosed Breakthrough Therapy designation from the U.S. FDA for essential thrombocythemia with Type 1 CALR mutations, along with Phase 1 data in ET and myelofibrosis showing hematologic responses, spleen volume reductions, symptom improvements and safety findings.
Beyond R&D, Incyte issues releases on leadership changes, board transitions, inducement equity grants and participation in major healthcare investor conferences. For investors and analysts, the INCY news page provides a centralized view of clinical, regulatory, corporate governance and capital markets developments affecting the company.
Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 16 new employees, totaling 13,351 shares of company common stock. The grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for March 3, 2025.
The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments of 25% each, contingent upon continued employment with the company.
Incyte (NASDAQ: INCY) announces multiple data presentations at the upcoming 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, March 7-11, 2025. The presentations will feature new data from their dermatology portfolio, including:
- Late-breaking Phase 3 data for ruxolitinib cream (Opzelura®) in prurigo nodularis from the TRuE-PN1 study
- Multiple presentations on ruxolitinib cream in atopic dermatitis, including long-term safety data from TRuE-AD1 and TRuE-AD2 Phase 3 studies, treatment patterns, and 52-week disease control in children aged 2-11 years
- Data for axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD)
Incyte (INCY) and Genesis Therapeutics have announced a strategic collaboration focused on developing novel small molecule medicines using Genesis' GEMS artificial intelligence platform. The partnership grants Incyte exclusive rights to develop and commercialize collaboration products.
Under the agreement, Genesis will receive a $30 million upfront payment and could earn up to $295 million in milestone payments per target. The collaboration initially focuses on two targets, with Incyte having the option to add a third target for a predetermined fee. Genesis is also eligible for tiered royalties on sales of approved collaboration products.
The partnership aims to leverage Genesis' proprietary AI technology, GEMS (Genesis Exploration of Molecular Space), to accelerate the discovery and optimization of small molecule compounds for Incyte-selected targets.
Incyte (INCY) has announced its participation in two major healthcare investor conferences in March 2025. The company will present at the Cowen 45th Annual Health Care Conference on Monday, March 3, at 11:10 am EST, and at the Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, at 9:20 am EST.
Both presentations will be accessible through live webcasts on Investor.Incyte.com and will remain available for replay for 30 days following the events.
Incyte (INCY) reported strong financial results for Q4 and full-year 2024, with total revenues reaching $1.2B (+16% Y/Y) in Q4 and $4.2B (+15% Y/Y) for FY2024. Key revenue drivers included Jakafi, with net revenues of $773M (+11% Y/Y) in Q4 and $2.8B (+8% Y/Y) for FY2024, and Opzelura, with net revenues of $162M (+48% Y/Y) in Q4 and $508M (+50% Y/Y) for FY2024.
The company provided 2025 guidance for Jakafi ($2,925-$2,975M) and Opzelura ($630-$670M). 2025 is expected to be a transformative year with four new product launches, four pivotal study readouts, at least three Phase 3 study initiations, and seven proof of concept study readouts. A key development includes ruxolitinib extended-release meeting FDA bioequivalence criteria, with submission planned by year-end 2025.
Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 24 new employees, totaling 16,301 shares of common stock. These grants were made under the Company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for February 3, 2025. The compensation committee approved these awards as inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years, with 25% of the shares vesting annually on each anniversary of the vesting commencement date, contingent upon continued employment with the company.
Incyte (Nasdaq:INCY) has announced its schedule for the fourth quarter and year-end 2024 financial results conference call and webcast. The event is set for 8:00 a.m. ET on Monday, February 10, 2025. The related press release will be issued at 7:00 a.m. ET on the same day.
The call will be accessible via domestic dial-in at 877-407-3042 and international dial-in at 201-389-0864, using the conference ID number 13751174. For those unable to attend, a replay will be available for thirty days. The U.S. replay dial-in number is 877-660-6853 and the international replay dial-in number is 201-612-7415, also using the conference ID number 13751174. Additionally, a live webcast with slides will be accessible at Investor.Incyte.com and available for replay for ninety days.
Incyte and Syndax Pharmaceuticals announced FDA approval of Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes, with U.S. launch expected in early February. Niktimvo is the first FDA-approved treatment targeting CSF-1R for chronic graft-versus-host disease (GVHD) in patients who failed at least two prior systemic therapies.
The approval was based on the AGAVE-201 trial results, where 75% of patients receiving 0.3 mg/kg every two weeks achieved response at six months. The approved dose is 0.3 mg/kg (max 35 mg) via intravenous infusion every two weeks for patients weighing at least 40 kg.
Notable adverse reactions occurred in 44% of patients, with 10% discontinuing treatment. The most common side effects included increased AST, infections, and decreased phosphate levels. The treatment has been added to NCCN Guidelines as a category 2A recommendation.
Incyte (NASDAQ:INCY) presented its growth strategy and 2025 milestones at the 43rd Annual J.P. Morgan Healthcare Conference. The company anticipates a transformational 2025 with four potential product launches, four pivotal trial readouts, seven proof of concept data readouts, and at least three Phase 3 study initiations.
Key highlights include the launch of Niktimvo™ (axatilimab-csfr) for chronic graft-versus-host disease, developments in tafasitamab following positive Phase 3 inMIND trial results for follicular lymphoma, povorcitinib's potential in hidradenitis suppurativa, mCALR-targeting molecule for myelofibrosis and essential thrombocythemia, and their CDK2 inhibitor for ovarian cancer treatment.
The company projects more than 10 high-impact launches across its portfolio by 2030, positioning itself for long-term growth.
Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 14 new employees, totaling 9,502 shares of company common stock. These grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for January 2, 2025. The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments of 25% each, contingent upon continued employment with the company.